NCT05868733 - A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa | Biotech Hunter

Enrollment

612

Participants

Timeline

Start Date

March 6, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2027

Conditions

Lassa Fever

Interventions

DRUG

Day 1 Lower Dose (2×106 pfu)

rVSV∆G-LASV-GPC

DRUG

Day 1 Higher Dose (1×107 pfu)

rVSV∆G-LASV-GPC

DRUG

Placebo

Trial Locations (3)

RECRUITING

Noguchi Memorial Institute for Medical Research (NMIMR), Accra

RECRUITING

PREVAIL_ John F. Kennedy Medical Center (JFK), Monrovia

RECRUITING

Walter Reed Program - Nigeria, Wuse

All Listed Sponsors

collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

lead

International AIDS Vaccine Initiative

NETWORK